Vanda Pharmaceuticals Inc. Advances Anti‑emetic Program While Challenging FDA Review Timelines

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) is actively pursuing two strategic fronts: the launch of a new clinical trial for its small‑molecule anti‑emetic, NEREUS™ (tradipitant), and a public campaign urging the U.S. Food and Drug Administration (FDA) to withdraw a proposed legislative amendment that would extend drug‑review timelines. The company’s actions underscore its commitment to addressing patient tolerability issues in the rapidly expanding glucagon‑like peptide‑1 (GLP‑1) receptor agonist market, while also expressing concerns over regulatory delays that could affect the development of its pipeline.

Thetis Trial: A Focus on Vomiting Prevention in GLP‑1 Therapy

On April 8, 2026, Vanda announced the initiation of the Thetis study, a multicenter, randomized, double‑blind, placebo‑controlled Phase 2 trial designed to evaluate oral tradipitant in patients starting high‑dose GLP‑1 receptor agonists such as semaglutide and tirzepatide. The trial’s primary endpoint is the proportion of patients who remain free from vomiting episodes during treatment, while the secondary endpoint assesses combined vomiting and significant nausea.

Previous data from an earlier Phase 2 study, disclosed in a November 15, 2025 press release, demonstrated a 50 % relative reduction in vomiting (29.3 % vs. 58.6 %) with tradipitant, achieving statistical significance (p = 0.0016). The new Thetis trial will build on these findings by enrolling patients who receive an initial high dose of a GLP‑1 agonist, thereby testing the drug’s efficacy under real‑world conditions where nausea and vomiting are most prevalent. Vanda expects topline results by the fourth quarter of 2026, with the possibility of subsequent data collection required for a New Drug Application (NDA).

Challenging FDA’s Legislative Proposal

In the same week, Vanda publicly criticized a proposal included in the FDA’s FY 2027 Congressional Budget Justification that would extend the agency’s drug‑review timelines. The company’s CEO and Chairman, Dr. Mihael H. Polymeropoulos, highlighted the potential adverse impact of longer review periods on the timely availability of new therapies, especially those addressing unmet needs such as anti‑emetics for GLP‑1 therapy. Vanda’s communication to the public and to investors called for the FDA to withdraw the proposal, arguing that extended timelines could delay patient access to essential medications.

Market Context and Financial Position

As of April 8, 2026, Vanda’s stock closed at $7.33 per share, trading within a 52‑week range of $3.81 to $9.94. The company’s market capitalization stands at approximately $440.35 million, with a price‑earnings ratio of -1.99, reflecting its ongoing investment in early‑stage development rather than current profitability. Vanda’s focus on central nervous system disorders and its emerging pipeline position it as a niche biopharmaceutical player within the broader biotechnology sector.

Conclusion

Vanda Pharmaceuticals Inc. is simultaneously advancing a clinically promising anti‑emetic candidate for GLP‑1 therapy patients and actively engaging in regulatory advocacy to safeguard efficient drug review processes. The outcomes of the Thetis trial and the FDA’s response to the proposed legislative amendment will both be pivotal in shaping the company’s trajectory and its ability to deliver value to patients and investors alike.